🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  2. Epetraborole

    AN2 Therapeutics

    MAC Lung Disease

    phase 3 small molecule terminated

    1 trial

  3. Erenumab

    United Therapeutics Europe Ltd

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  4. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  5. Ertapenem

    Iterum Therapeutics plc

    Intra Abdominal Infections

    phase 3 small molecule completed

    1 trial

  6. EryDex Low dose DSP

    Quince Therapeutics

    Nervous System Disease

    phase 3 small molecule completed

    1 trial

  7. EryDex System

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 other terminated

    1 trial

  8. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial

  9. Estradiol

    TherapeuticsMD

    Vulvovaginal Atrophy

    phase 3 small molecule completed

    1 trial

  10. Estradiol

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    2 trials

  11. Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Primary Dysmenorrhea

    phase 3 small molecule completed

    1 trial

  12. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  13. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  14. Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  15. Everolimus

    United Therapeutics Europe Ltd

    Pediatric Heart Transplantation

    phase 3 small molecule active

    1 trial

  16. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  17. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  18. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  19. Exparel

    Pacira Ireland Limited

    Postoperative Pain Management

    phase 3 small molecule completed

    3 trials

  20. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

  21. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  22. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  23. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  24. FF/UMEC/VI

    Grace Therapeutics

    Asthma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources